The Phase I study will vaccinate twenty healthy volunteers via...

The Phase I study will vaccinate twenty healthy volunteers via intradermal injection into the
forearms with a goal to examine the safety of the vaccine, as well as detect if an antibody and
T-cell response can be generated by people.
Along with safety data, the results will indicate if the vaccine can stimulate an antibody
(protective) response as well as T-cell response (therapeutic). The importance of the T-cell
response is it indicates the potential for the vaccine to be used as a treatment against herpes.
“This is the beginning of an exciting period for our herpes vaccine. We have seen very
encouraging results from animal studies and we expect pivotal data showing that our vaccine,
which incorporates our patented optimisation technology, to produce similar immune responses
in the clinic,” said Professor Frazer.
The outcomes of the Phase I trial will demonstrate the vaccine’s safety and how well tolerated it
is, as well as determining the effective dose and showing that the vaccine generates a robust
immune response.